Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Paris Regional Cancer Center Lab
mi
from
Paris, TX
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Paris Regional Cancer Center Lab
mi
from
Paris, TX
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Texas Cancer Center - Sherman
mi
from
Sherman, TX
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Texas Cancer Center - Sherman
mi
from
Sherman, TX
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Tyler Cancer Center
mi
from
Tyler, TX
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Deke Slayton Cancer Center
mi
from
Webster, TX
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Deke Slayton Cancer Center
mi
from
Webster, TX
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Oncology & Hematology Associates Of Southwest Virginia, Inc.
mi
from
Salem, VA
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Oncology & Hematology Associates Of Southwest Virginia, Inc.
mi
from
Salem, VA
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Puget Sound Cancer Centers
mi
from
Edmonds, WA
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Puget Sound Cancer Centers
mi
from
Edmonds, WA
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Puget Sound Cancer Centers
mi
from
Seattle, WA
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Puget Sound Cancer Centers
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Cancer Care Northwest
mi
from
Spokane, WA
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Northwest Cancer Specialists
mi
from
Vancouver, WA
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Northwest Cancer Specialists
mi
from
Vancouver, WA
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Parallel Phase I Study of Ixabepilone Plus Lapatinib and Ixabepilone Plus Lapatinib Plus Capecitabine in Subjects With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2016
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Parallel Phase I Study of Ixabepilone Plus Lapatinib and Ixabepilone Plus Lapatinib Plus Capecitabine in Subjects With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2016
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Parallel Phase I Study of Ixabepilone Plus Lapatinib and Ixabepilone Plus Lapatinib Plus Capecitabine in Subjects With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2016
Local Institution
mi
from
Brisbane,
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Parallel Phase I Study of Ixabepilone Plus Lapatinib and Ixabepilone Plus Lapatinib Plus Capecitabine in Subjects With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2016
Local Institution
mi
from
Brisbane,
Click here to add this to my saved trials
Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation
Pilot Study to Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation in Women Treated for Node Positive Breast Cancer With Three- Dimensional Conformal Radiation Therapy (3DCRT)
Status: Enrolling
Updated:  2/9/2016
Froedtert Hospital
mi
from
Milwaukee, WI
Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation
Pilot Study to Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation in Women Treated for Node Positive Breast Cancer With Three- Dimensional Conformal Radiation Therapy (3DCRT)
Status: Enrolling
Updated: 2/9/2016
Froedtert Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy
Evaluation of an Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy
Status: Enrolling
Updated:  2/10/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy
Evaluation of an Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy
Status: Enrolling
Updated: 2/10/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
Status: Enrolling
Updated:  2/11/2016
University of Connecticut
mi
from
Farmington, CT
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
Status: Enrolling
Updated: 2/11/2016
University of Connecticut
mi
from
Farmington, CT
Click here to add this to my saved trials
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
Status: Enrolling
Updated:  2/11/2016
Women's Cancer Care Associates
mi
from
Albany, NY
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
Status: Enrolling
Updated: 2/11/2016
Women's Cancer Care Associates
mi
from
Albany, NY
Click here to add this to my saved trials
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
Status: Enrolling
Updated:  2/11/2016
Albert Einstein College of Medicine
mi
from
Bronx, NY
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
Status: Enrolling
Updated: 2/11/2016
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
Status: Enrolling
Updated:  2/11/2016
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
Status: Enrolling
Updated: 2/11/2016
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
Status: Enrolling
Updated:  2/11/2016
Weill Medical College of Cornell University
mi
from
New York, NY
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
Status: Enrolling
Updated: 2/11/2016
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
University of Chicago
mi
from
Chicago, IL
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
Bodyaesthetic
mi
from
St. Louis, MO
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
Bodyaesthetic
mi
from
St. Louis, MO
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
Aesthetic Plastic Surgery
mi
from
Great Neck, NY
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
Aesthetic Plastic Surgery
mi
from
Great Neck, NY
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
Columbia University
mi
from
New York, NY
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
New York Group
mi
from
Tarrytown, NY
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
New York Group
mi
from
Tarrytown, NY
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
UT Southwestern
mi
from
Dallas, TX
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
UT Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
Northwestern University
mi
from
Chicago, IL
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification
Status: Enrolling
Updated:  2/11/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification
Status: Enrolling
Updated: 2/11/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant
Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/11/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant
Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/11/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer
Does Blocking Proinflammatory Cytokines Diminish Cancer-Related Fatigue?
Status: Enrolling
Updated:  2/12/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer
Does Blocking Proinflammatory Cytokines Diminish Cancer-Related Fatigue?
Status: Enrolling
Updated: 2/12/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation
Status: Enrolling
Updated:  2/12/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation
Status: Enrolling
Updated: 2/12/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/12/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/12/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/12/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/12/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Universito of Birmingham atAlabama
mi
from
Birmingham, AL
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Universito of Birmingham atAlabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Arizona Oncology Associates
mi
from
Tucson, AZ
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Arizona Oncology Associates
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Marin Cancer Center
mi
from
Greenbrae, CA
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Marin Cancer Center
mi
from
Greenbrae, CA
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
PMK Medical Group, Inc.
mi
from
Oxnard, CA
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
PMK Medical Group, Inc.
mi
from
Oxnard, CA
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Florida Cancer Research Institute
mi
from
Plantation, FL
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Florida Cancer Research Institute
mi
from
Plantation, FL
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Piedmont Healthcare
mi
from
Altanta, GA
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Piedmont Healthcare
mi
from
Altanta, GA
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Piedmont Fayette Hospital
mi
from
Fayetteville, GA
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Piedmont Fayette Hospital
mi
from
Fayetteville, GA
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
University of Chicago
mi
from
Chicago, IL
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Beaumont Health Systems
mi
from
Royal Oak, MI
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Beaumont Health Systems
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Memorial Medical Center
mi
from
Las Cruces, NM
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Memorial Medical Center
mi
from
Las Cruces, NM
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Cancer Center of the Carolinas
mi
from
Greenville, SC
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Cancer Center of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology, P.A. -Amarillo
mi
from
Amarillo, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology, P.A. -Amarillo
mi
from
Amarillo, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology-Austin Central
mi
from
Austin, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology-Austin Central
mi
from
Austin, TX
Click here to add this to my saved trials